Copyright
©The Author(s) 2022.
World J Clin Cases. Aug 6, 2022; 10(22): 7728-7737
Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7728
Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7728
Table 3 mean ± SD values of treatment delivery parameters (and range)
Dosimetric verification | Point dose measurements (%) | ArcCHECK (2%/2 mm) (%) | ArcCHECK (3%/3 mm) (%) | Portal dosimetry (2%/2 mm) (%) |
Head and neck | 0.26 ± 1.1 (-0.22-1.92) | 95.5 ± 1.8 (93.2-97.7) | 99.4 ± 0.5 (98.8-100) | 97.8 ± 2.4 (93.3-100) |
Chest | 1 ± 0.6 (0.45-2.18) | 97.63 ± 1.1 (96.1-98.4) | 99.2 ± 0.8 (97.9-100) | 89.7 |
Abdomen | 1.11 ± 0.7 (0.23-2.01) | 97.1 ± 2.0 (95.5-99.3) | 98.8 ± 1.5 (96.5-99.7) | 96 |
Pelvic | -0.15 ± 0.7 (-0.99-1.38) | 96.0 ± 2.2 (94.2-99.2) | 99 ± 1.4 (96.3-100) | 98.4 ± 2.4 (98.1-98.6) |
Spine and bone | 0.2 ± 1.8 (-1.8-2.72) | 96.5 ± 1.8 (93.6-97.8) | 99.2 ± 0.9 (97.9-100) | 93.2 ± 6.4 (88.6-97.7) |
Total | 0.42 ± 1 (-1.8-2.72) | 96.4 ± 1.8 (93.3-99.3) | 99.1 ± 1.1 (96.3-100) | 96.7 ± 3.4 (88.6-100) |
- Citation: Wang GY, Zhu QZ, Zhu HL, Jiang LJ, Zhao N, Liu ZK, Zhang FQ. Clinical performance evaluation of O-Ring Halcyon Linac: A real-world study. World J Clin Cases 2022; 10(22): 7728-7737
- URL: https://www.wjgnet.com/2307-8960/full/v10/i22/7728.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i22.7728